2015
   Hersonissos, Crete, Greece

I-01 Jae Eun Ahn Modelling and Simulation of Motor Symptom Measurements in Parkinson’s Disease after L-Dopa Administration Wednesday 10:45-12:15

I-02 Mona Alameddine Optimal phase 2 dose selection based on the relationship between exposure and target occupancy Wednesday 10:45-12:15

I-03 Hesham Al-Sallami Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients Wednesday 10:45-12:15

I-04 Oskar Alskär Interspecies scaling of the integrated glucose insulin model Wednesday 10:45-12:15

I-05 Robert Andersson Dose-response-time modelling - Second generation turnover model with integral feedback control Wednesday 10:45-12:15

I-06 Yusuke Asai Mathematical modeling by random ordinary differential equations and their numerical schemes Wednesday 10:45-12:15

I-07 Hyun-moon Back A Mechanistic multicompartmental Pharmacokinetic model for food effect of fenofibrate Wednesday 10:45-12:15

I-08 Kathryn Ball Semi-physiological population pharmacokinetic modelling of renal transporter-mediated clinical drug-drug interactions Wednesday 10:45-12:15

I-09 Guillaume Baneyx Population PK model describing multiple peaks after a single oral administration of buparlisib in healthy volunteers. Wednesday 10:45-12:15

I-10 Charlotte Barker Population pharmacokinetics of benzylpenicillin in neonates in routine care Wednesday 10:45-12:15

I-11 Christian Bartels Relation of FEV1 to COPD Patient Outcomes: A patient level pooled analysis of COPD clinical trials Wednesday 10:45-12:15

I-12 Ana Bastos A joint population pharmacokinetic model of total and unbound temocillin serum concentrations in hemodialysis patients Wednesday 10:45-12:15

I-13 Stephan Benay Linear compartmental pharmacokinetic models : from continuous-time differential form to discrete time auto-regression with extra inputs. Application to system identification. Wednesday 10:45-12:15

I-14 Linnea Bergenholm Population PKPD modelling of QRS and PR intervals in conscious dogs. Wednesday 10:45-12:15

I-15 Aliénor Bergès Time-to-event (TTE) modelling in drug safety evaluation: a case study Wednesday 10:45-12:15

I-16 Jan Berkhout Systems pharmacology modeling describing osteoporotic disease progression in a population of postmenopausal women receiving placebo or alendronate Wednesday 10:45-12:15

I-17 Marival Bermejo Level A IVIVC for Carbamazepine IR formulations and in vitro dissolution specifications using one-step approaches Wednesday 10:45-12:15

I-18 Julie Bertrand Bayesian Variable Selection for high-throughput genetic association analysis in population pharmacokinetics. Wednesday 10:45-12:15

I-19 Shanshan Bi Model-Based Meta-Analysis (MBMA) for direct-acting antiviral (DAA) agents in the Treatment of Chronic HCV Wednesday 10:45-12:15

I-20 Andrzej Bienczak Population Pharmacokinetic/Pharmacogenetic Analysis of Nevirapine in African Children Wednesday 10:45-12:15

I-21 Konstantinos Biliouris MatVPC: A User-friendly Matlab Tool for the Automatic Construction of Visual Predictive Checks and Quantified Visual Predictive Checks of Systems Pharmacology Models Wednesday 10:45-12:15

I-22 Sofia Birgersson New micronized formulation does not affect the population pharmacokinetic properties of artemisinin. Wednesday 10:45-12:15

I-23 Henrik Bjugård Nyberg Influence of Covariance Step Success on Final Parameter Estimates Wednesday 10:45-12:15

I-24 Irina Bondareva Population modeling of changes in steady–state pharmacokinetics of carbamazepine (CBZ) due to antiepileptic drug-drug interactions from therapeutic drug monitoring (TDM) data Wednesday 10:45-12:15

I-25 Jennifer Bonner Building of a virtual paediatric cancer population for physiologically-based pharmacokinetic modelling and simulation in neonates, infants, and children Wednesday 10:45-12:15

I-26 Boram Ohk Population pharmacokinetics of Fimasartan Wednesday 10:45-12:15

I-27 Elisa Borella Predictive assessments of pharmacokinetic alterations in subjects with renal disease Wednesday 10:45-12:15

I-28 Jens Markus Borghardt A New Parameterisation to Describe Parallel Absorption Processes After Drug Inhalation Wednesday 10:45-12:15

I-29 Rolien Bosch A mechanism-based model is able to simultaneously explain the effect of rhLCAT and HDL mimetics on biomarkers of reverse cholesterol transport Wednesday 10:45-12:15

I-30 Marion Bouillon-Pichault Longitudinal Model-Based Meta-Analysis in Type 2 Diabetes: Assessment of link between fasting plasma glucose and Hba1c. Wednesday 10:45-12:15

I-31 Karl Brendel How to consider microdosing data in a population PK analysis? Wednesday 10:45-12:15

I-32 Annika Brings Modelling and simulation of adverse drug effects on heart rate in the anaesthetized mouse Wednesday 10:45-12:15

I-33 Jantine Brussee Population modeling of cytochrome P450 mediated drug metabolism and oral absorption in preterm neonates receiving intravenous and oral midazolam in a cross-over study Wednesday 10:45-12:15

I-34 Simon Buatois Using Item response theory to yield information from the MDS-UPDRS items in Parkinson’s disease clinical trials Wednesday 10:45-12:15

I-35 Núria Buil Bruna Population PK/PD modelling of the biomarker and progression free survival effects of Lanreotide Autogel in patients with non-functioning gastroenteropancreatic neuroendocrine tumors Wednesday 10:45-12:15

I-36 Theresa Cain Application of Simcyp’s R Library Package in Simulation and Prediction of Metoprolol Compliance Using a Single Plasma Concentration Sample Wednesday 10:45-12:15

I-37 Sophie Callies Dose projection and prediction of PK/PD response - a bench to bedside example for LY drug. Wednesday 10:45-12:15

I-38 Elisa Calvier Extrapolation potential of semi-physiological covariate models to newborns: a simulation-based study Wednesday 10:45-12:15

I-39 Tim Cardilin Modelling and Analysis of Tumor Growth Inhibition for Combination Therapy using Tumor Static Concentration Curves Wednesday 10:45-12:15

I-40 Letizia Carrara Modelling the effect of Sunitinib given alone and in combination with CPT-11 on the tumor growth in xenografted mice Wednesday 10:45-12:15

I-41 Massimo Cella Use of a TMDD model in the translational development of a BDNF-neutralizing monoclonal antibody Wednesday 10:45-12:15

I-42 Dong Woo Chae Mechanistic Modeling of Telmisartan Blood Pressure Lowering Effect in Human Wednesday 10:45-12:15

I-43 Pascal Chanu Model-based simulation assessment of Personalized Healthcare strategies. A case for siponimod in multiple sclerosis. Wednesday 10:45-12:15

I-44 Aziz Chaouch Approximate prediction percentiles for non-linear mixed effects models with continuous response Wednesday 10:45-12:15

I-45 Christophe Chassagnole Modelling Synergistic Immunotherapy Combinations with Virtual Tumour Wednesday 10:45-12:15

I-46 Clarisse Chavanne How to simulate pediatric pharmacokinetic (PK) exposures using a population PK dataset composed of incomplete age groups. Wednesday 10:45-12:15

I-47 Tina Checchio Mixed Effects Analysis of Non-compartmental Pharmacokinetic Parameters of Tofacitinib from 16 Phase 1 Studies. Wednesday 10:45-12:15

I-48 Pierre Chelle Assessment of Endogenous Thrombin Potential predictive potential of Thrombin Generation mechanistic models with Hemophilic A patients Wednesday 10:45-12:15

I-49 Chunli Chen Application of the Multistate Tuberculosis Disease Model for Studying Pharmacokinetics and Pharmacodynamics in a Chronic Tuberculosis Mouse Model Wednesday 10:45-12:15

I-50 Mohammed Cherkaoui Rbati Mechanistic Model to Predict DDIs in the Liver Wednesday 10:45-12:15

I-51 Manoranjenni Chetty Emerging covariates on the pharmacokinetics of monoclonal antibodies: Do current PBPK models account for the covariates identified in POPPK studies? Wednesday 10:45-12:15

I-52 Maxwell Chirehwa Model based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of first-pass hepatic extraction Wednesday 10:45-12:15

I-53 Jason Chittenden Evaluation of stepwise covariate model selection with Bayesian models Wednesday 10:45-12:15

I-54 Palang Chotsiri Population pharmacokinetic and cardiotoxic modelling of the antimalarial drug piperaquine Wednesday 10:45-12:15

I-55 Steve Choy Modelling the disease progression of diabetes from healthy to overtly diabetic in ZDSD rats Wednesday 10:45-12:15

I-56 Eirini Christodoulou Pharmacokinetics of Crocus sativus L. aqueous extract after peros and intravenous administration to C57/BL6J mice Wednesday 10:45-12:15

I-57 Laurent Claret A comparison of two stage and joint tumor growth inhibition-progression free survival modeling approach to simulate clinical outcome in oncology Wednesday 10:45-12:15

I-58 Pieter Colin Towards TDM-guided dosing for cefepime in the critically ill Wednesday 10:45-12:15

I-59 Francois Combes Population Pharmacodynamic Modeling and Simulation of Anti-Obesity Clinical Trials to Explore Longitudinal Weight Loss Wednesday 10:45-12:15

I-60 Emmanuelle Comets Joint modelling of iron and hepcidin during the menstrual cycle Wednesday 10:45-12:15

I-61 Ana Margarita Contreras Sandoval Towards a platform PK/PD model for an anti-PD-L1 monoclonal antibody through a preclinical syngeneic melanoma mouse model Wednesday 10:45-12:15

I-62 Teresa Dalla Costa Population analysis of levofloxacin in plasma, lung and prostrate measured by microdialysis in Wistar rats after intravenous and intratracheal administration Wednesday 10:45-12:15

I-63 André Dallmann Development of a Physiologically-Based Pharmacokinetic Population Model for Pregnant Women Wednesday 10:45-12:15

I-64 Adam Darwich Gastric emptying and its covariates Wednesday 10:45-12:15

I-65 Camila De Almeida PKPD-efficacy modelling of AZD9496, a novel oral selective estrogen receptor downregulator Wednesday 10:45-12:15

I-66 Pieter De Cock Population cefazolin pharmacokinetics before, during and after cardiopulmonary bypass in children undergoing cardiac surgery Wednesday 10:45-12:15

I-67 Sjoerd De Hoogd Population pharmacokinetics of morphine and its metabolites M3G and M6G in morbidly obese patients and healthy volunteers Wednesday 10:45-12:15

I-68 Mailys De Sousa Mendes Prediction of human foetal pharmacokinetic profile using transplacental parameters from ex-vivo human placenta perfusion model and pregnancy-Physiologically Based Pharmacokinetic models Wednesday 10:45-12:15

I-69 Elien De Thaye Model-based comparison of modified-release metoprolol formulations in beagle dogs and rabbits Wednesday 10:45-12:15

I-70 Femke de Velde Nonlinear absorption pharmacokinetics of amoxicillin Wednesday 10:45-12:15

I-71 Brenda de Winter Population pharmacokinetics of intravenous albuterol in children with status asthmaticus Wednesday 10:45-12:15

I-72 Willem de Winter A dynamic population PK/PD model to assess the effect of once daily versus twice daily dosing regimens on the relationship between canagliflozin plasma exposure and HbA1c response Wednesday 10:45-12:15

I-73 Wilbert de Witte What is the influence of diffusion-limited binding on in vivo target occupancy profiles? Wednesday 10:45-12:15

I-74 Francesca Del Bene Modelling potential drug-drug interaction risks with a combined top-down/bottom-up approach Wednesday 10:45-12:15

I-76 Paolo Denti Population Pharmacokinetics of Ofloxacin in South African children Wednesday 10:45-12:15

I-77 Cheikh Diack An empirical drug-disease model to characterize the effect of Ranibizumab on disease progression in wet AMD patients Wednesday 10:45-12:15